**An EAI with a Shorter Needle Length May Help Reduce the Risk of Certain Accidental EAI-Related Injection Injuries in Infants and Toddlers Weighing 16.5 to 33 lbs (7.5 to 15 kg)**

AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical attention after using AUVI-Q.

**EpiPen® (epinephrine auto-injectors) are designed for use in people weighing 30 to 143 lbs (13.6 to 65 kg). They are not designed for use in infants or children weighing less than 30 lbs (13.6 kg).**

**FDA-approved AUVI-q 0.1 mg is the first and only EAI specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and toddlers weighing 16.5 to 33 lbs (7.5 to 15 kg) who are at risk for or have a history of serious allergic reactions.**

**The AUVI-q 0.1 mg auto-injector offers a lower dose of epinephrine and a shorter exposed needle length (approximately 7.4 mm) than current FDA-approved EAI-0.3 mg and 0.15 mg epinephrine auto-injectors. AUVI-q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical attention after using AUVI-Q.**

**Anaphylaxis is a medical emergency and requires immediate treatment; however, diagnosis of anaphylaxis in infants and toddlers can be difficult.**

**Common side effects include fast, irregular or ‘pounding’ heartbeat, sweating, shakiness, headache, pale skin, weakness, dizziness, nausea and vomiting, and feeling of over excitement, nervousness, or anxiety.**

**Rarely, patients who use AUVI-Q may develop infections at the injection site within a few days of an additional dose of epinephrine.**

**EPIFEN® or epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.**

**An Epinephrine auto-injector should be used only when you or a caretaker or other person present recognizes the symptoms of anaphylaxis.**

**Diagnosis of anaphylaxis can be difficult.**

**Recognizing Anaphylactic Reactions in Infants and Toddlers Weighing 16.5 to 33 lbs (7.5 to 15 kg)**

**Emergency Department Visits for Anaphylaxis Among Children Four Years Old and Younger Increased by 129.8 Percent.**

**NOTE: AUVI-q 0.1 mg will be available starting May 1st.**

**Visit www.auvi-q.com for more information.**

**Unmet Medical Need in the Emergency Treatment of Life-Threatening Allergic Reactions**

**Epinephrine auto-injectors (EAI) represent the standard of care for the treatment of anaphylaxis in the out-of-the-hospital setting**, yet until now there has been no FDA-approved epinephrine auto-injector (EAI) for the treatment of children weighing 16.5 to 33 lbs (7.5 to 15 kg).

**Indication**

AUVI-Q (epinephrine injection, USP) is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.

**Important Safety Information**

AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after using AUVI-Q.

**EPIFEN® and EPIFEN® Jr should only be injected into your outer thigh, through clothing if necessary.** If you inject EPIFEN® Jr into a vein, artery, or muscle, you may have an allergic reaction. AUVI-Q should only be injected into your outer thigh, through clothing if necessary.

**The AUVI-q 0.1 mg auto-injector offers a lower dose of epinephrine and a shorter exposed needle length (approximately 7.4 mm) than current FDA-approved EAI-0.3 mg and 0.15 mg epinephrine auto-injectors. AUVI-q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical attention after using AUVI-Q.**

**An EAI with a Shorter Needle Length May Help Reduce the Risk of Certain Accidental EAI-Related Injection Injuries in Infants and Toddlers Weighing 16.5 lbs (7.5 kg) to 33 lbs (15 kg).**

**According to a study of 51 infants, 43 percent of children weighing 16.5 lbs (7.5 kg) to 33 lbs (15 kg) treated with a 0.15 mg EAI having a standard 12.7 mm needle length were at risk of having the needle strike the bone.**

**A study suggests that for infants and toddlers weighing between 16.5 and 33 lbs (7.5-15 kg), an optimal EAI needle length of 7.8 mm is recommended.**

**If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use AUVI-Q. Be sure to tell your healthcare provider about all of your medical conditions and the medicines you take, especially medicines for asthma.**

**Most common symptoms of anaphylaxis are hives, nausea, vomiting, and swelling for infants under the age of 2, and hives, swelling, and wheezing for toddlers aged 2 and older.**

**Important Safety Information**

AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after using AUVI-Q.